|
Compartment/TIL subtype
|
ER status
|
PR status
|
Her2/neu
|
|---|
| |
-
|
+
|
p-value
|
-
|
+
|
p-value
|
-
|
+
|
p-value
|
|---|
|
Total
| | | | | | | | | |
|---|
|
CD4
+
|
25.1 ± 29.7
|
15.6 ± 22.9
|
< 0.001
|
12.4 ± 19.3
|
17.9 ± 25.2
|
0.008
|
17.0 ± 24.5
|
22.4 ± 27.4
|
0.023
|
|
FOXP3
+
|
11.9 ± 16.1
|
6.9 ± 11.3
|
< 0.001
|
8.6 ± 13.4
|
6.7 ± 10.9
|
0.203
|
7.6 ± 12.6
|
10.6 ± 13.0
|
< 0.001
|
|
Intratumoral
| | | | | | | | | |
|
CD4
+
|
17.5 ± 23.4
|
10.7 ± 18.5
|
< 0.001
|
8.2 ± 13.6
|
12.7 ± 21.6
|
0.032
|
11.7 ± 19.7
|
15.6 ± 21.8
|
0.036
|
|
FOXP3
+
|
7.0 ± 12.8
|
3.0 ± 7.0
|
< 0.001
|
4.0 ± 9.2
|
2.7 ± 6.1
|
0.12
|
3.7 ± 8.7
|
4.7 ± 8.1
|
0.009
|
- Mean ± SD, counts of immunoreactive lymphocytes CD4+ and FOXP3+ Wilcoxon Rank Sum Test; *after adjustment for multiple comparisons, only p < 0.001 was considered statistically significant
